• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

行政数据库与乳腺癌治疗数据医学图表相比的有效性

Validity of Administrative Databases in Comparison to Medical Charts for Breast Cancer Treatment Data.

作者信息

Weerasinghe Ashini, Smith Courtney R, Majpruz Vicky, Pandya Anjali, Blackmore Kristina M, Holloway Claire M B, Segal-Nadlere Roanne, Paroschy Harris Cathy, Hendry Ashley, Hey Amanda, Kornecki Anat, Lougheed George, Maier Barbara-Anne, Marchand Patricia, McCready David, Rand Carol, Raphael Simon, Sehgal Neelu, Chiarelli Anna M

机构信息

Prevention and Cancer Control, Cancer Care Ontario, 620 University Avenue, Toronto, ON, Canada M5G 2L7.

Dalla Lana School of Public Health, University of Toronto, 155 College Street, 6th Floor, Toronto, ON, Canada M5T 3M7.

出版信息

J Cancer Epidemiol. 2018 May 14;2018:9218595. doi: 10.1155/2018/9218595. eCollection 2018.

DOI:10.1155/2018/9218595
PMID:29861727
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC5976924/
Abstract

OBJECTIVE

Medical chart abstraction is the gold standard for collecting breast cancer treatment data for monitoring and research. A less costly alternative is the use of administrative databases. This study will evaluate administrative data in comparison to medical charts for breast cancer treatment information.

STUDY DESIGN AND SETTING

A retrospective cohort design identified 2,401 women in the Ontario Breast Screening Program diagnosed with invasive breast cancer from 2006 to 2009. Treatment data were obtained from the Activity Level Reporting and Canadian Institute of Health Information databases. Medical charts were abstracted at cancer centres. Sensitivity, specificity, positive and negative predictive value, and kappa were calculated for receipt and type of treatment, and agreement was assessed for dates. Logistic regression evaluated factors influencing agreement.

RESULTS

Sensitivity and specificity for receipt of radiotherapy (92.0%, 99.3%), chemotherapy (77.7%, 99.2%), and surgery (95.8%, 100%) were high but decreased slightly for specific radiotherapy anatomic locations, chemotherapy protocols, and surgeries. Agreement increased by radiotherapy year (trend test, < 0.0001). Stage II/III compared to stage I cancer decreased odds of agreement for chemotherapy (OR = 0.66, 95% CI: 0.48-0.91) and increased agreement for partial mastectomy (OR = 3.36, 95% CI: 2.27-4.99). Exact agreement in treatment dates varied from 83.0% to 96.5%.

CONCLUSION

Administrative data can be accurately utilized for future breast cancer treatment studies.

摘要

目的

病历摘要提取是收集乳腺癌治疗数据以进行监测和研究的金标准。一种成本较低的替代方法是使用行政数据库。本研究将评估行政数据与病历在乳腺癌治疗信息方面的差异。

研究设计与背景

一项回顾性队列研究设计确定了安大略省乳腺癌筛查项目中2006年至2009年被诊断为浸润性乳腺癌的2401名女性。治疗数据来自活动水平报告和加拿大卫生信息研究所的数据库。在癌症中心提取病历摘要。计算了治疗的接受情况和类型的敏感性、特异性、阳性和阴性预测值以及kappa值,并评估了日期的一致性。逻辑回归评估了影响一致性的因素。

结果

放疗(92.0%,99.3%)、化疗(77.7%,99.2%)和手术(95.8%,100%)接受情况的敏感性和特异性较高,但对于特定放疗解剖部位、化疗方案和手术,敏感性和特异性略有下降。放疗年份的一致性有所增加(趋势检验,<0.0001)。与I期癌症相比,II/III期癌症化疗一致性的几率降低(OR = 0.66,95% CI:0.48 - 0.91),部分乳房切除术的一致性增加(OR = 3.36,95% CI:2.27 - 4.99)。治疗日期的精确一致性在83.0%至96.5%之间。

结论

行政数据可准确用于未来的乳腺癌治疗研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e36b/5976924/6fe752004006/JCE2018-9218595.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e36b/5976924/e5e524790b22/JCE2018-9218595.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e36b/5976924/6fe752004006/JCE2018-9218595.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e36b/5976924/e5e524790b22/JCE2018-9218595.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e36b/5976924/6fe752004006/JCE2018-9218595.002.jpg

相似文献

1
Validity of Administrative Databases in Comparison to Medical Charts for Breast Cancer Treatment Data.行政数据库与乳腺癌治疗数据医学图表相比的有效性
J Cancer Epidemiol. 2018 May 14;2018:9218595. doi: 10.1155/2018/9218595. eCollection 2018.
2
Quality of hospital discharge and physician data for type of breast cancer surgery.乳腺癌手术类型的医院出院及医生数据质量。
Med Care. 2000 Jan;38(1):99-107. doi: 10.1097/00005650-200001000-00011.
3
Ascertaining invasive breast cancer cases; the validity of administrative and self-reported data sources in Australia.确定浸润性乳腺癌病例;澳大利亚行政和自我报告数据源的有效性。
BMC Med Res Methodol. 2013 Feb 11;13:17. doi: 10.1186/1471-2288-13-17.
4
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.用于指导早期乳腺癌女性辅助化疗决策的基因表达谱分析:基于证据的经济分析
Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1.
5
A comparison of comorbidities obtained from hospital administrative data and medical charts in older patients with pneumonia.比较老年肺炎患者的医院管理数据和病历中的合并症。
BMC Health Serv Res. 2011 May 18;11:105. doi: 10.1186/1472-6963-11-105.
6
Validity of Administrative Data in Identifying Cancer-related Events in Adolescents and Young Adults: A Population-based Study Using the IMPACT Cohort.利用 IMPACT 队列对青少年和年轻成年人癌症相关事件进行基于人群的研究:行政数据的有效性。
Med Care. 2018 Jun;56(6):e32-e38. doi: 10.1097/MLR.0000000000000777.
7
Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.针对40至49岁患乳腺癌平均风险女性的乳腺钼靶筛查:一项基于证据的分析。
Ont Health Technol Assess Ser. 2007;7(1):1-32. Epub 2007 Jan 1.
8
Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women.哮喘女性中与妊娠相关变量的行政数据库与病历之间的一致性
Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):345-53. doi: 10.1002/pds.1558.
9
10
Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer.用于识别早期浸润性乳腺癌后第二乳腺癌事件的行政数据算法。
J Natl Cancer Inst. 2012 Jun 20;104(12):931-40. doi: 10.1093/jnci/djs233. Epub 2012 Apr 30.

引用本文的文献

1
Treatment, healthcare utilization and outcomes in patients with glioblastoma in Ontario: a 10-year cohort study.安大略省胶质母细胞瘤患者的治疗、医疗保健利用和结局:一项 10 年队列研究。
J Neurooncol. 2024 Jul;168(3):473-485. doi: 10.1007/s11060-024-04690-7. Epub 2024 May 3.
2
Variation in Access to Palliative Radiotherapy in Prostate Cancer: A Population-Based Study in Canada.前列腺癌姑息性放疗可及性的差异:一项基于加拿大人群的研究
Cureus. 2024 Feb 20;16(2):e54582. doi: 10.7759/cureus.54582. eCollection 2024 Feb.
3
Treatment and Mortality Following Cancer Diagnosis Among People With Non-affective Psychotic Disorders in Ontario, Canada: A Retrospective Cohort Study.

本文引用的文献

1
Health system costs for stage-specific breast cancer: a population-based approach.特定分期乳腺癌的卫生系统成本:基于人群的方法。
Curr Oncol. 2014 Dec;21(6):281-93. doi: 10.3747/co.21.2143.
2
Clinical and prognostic factors associated with diagnostic wait times by breast cancer detection method.按乳腺癌检测方法划分的与诊断等待时间相关的临床和预后因素。
Springerplus. 2014 Mar 6;3:125. doi: 10.1186/2193-1801-3-125. eCollection 2014.
3
Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study.
加拿大安大略省非情感性精神障碍患者癌症诊断后的治疗与死亡率:一项回顾性队列研究
Schizophr Bull. 2024 Dec 20;51(1):75-84. doi: 10.1093/schbul/sbae013.
4
Population-based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non-metastatic muscle-invasive bladder cancer.基于人群的非转移性肌层浸润性膀胱癌患者围手术期化疗使用、需要住院治疗的干预措施和动脉栓塞事件的分析。
Cancer Med. 2021 Apr;10(8):2636-2644. doi: 10.1002/cam4.3805. Epub 2021 Mar 12.
基于病历回顾或医疗保险索赔定义乳腺癌护理:来自疾病预防控制中心护理模式研究的信息。
Ann Epidemiol. 2012 Nov;22(11):807-13. doi: 10.1016/j.annepidem.2012.08.001. Epub 2012 Sep 1.
4
Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure.八种综合医疗服务提供组织的行政临床数据在捕捉乳腺癌化疗暴露方面的有效性。
Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):673-80. doi: 10.1158/1055-9965.EPI-11-1075. Epub 2012 Feb 15.
5
Favourable prognostic factors of subsequent screen-detected breast cancers among women aged 50-69.50-69 岁女性中后续经筛检发现的乳腺癌的有利预后因素。
Eur J Cancer Prev. 2012 Nov;21(6):499-506. doi: 10.1097/CEJ.0b013e328350b0f4.
6
Stage at diagnosis and comorbidity influence breast cancer survival in First Nations women in Ontario, Canada.在加拿大安大略省,诊断时的分期和合并症影响了第一民族女性的乳腺癌生存情况。
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2160-7. doi: 10.1158/1055-9965.EPI-11-0459. Epub 2011 Jul 29.
7
Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer.利用行政索赔和医疗记录来确定乳腺癌患者使用个性化药物的权衡。
Med Care. 2011 Jun;49(6):e1-8. doi: 10.1097/MLR.0b013e318207e87e.
8
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).美国临床肿瘤学会/美国病理学家学会关于乳腺癌雌激素和孕激素受体免疫组织化学检测的指南建议(未删节版)。
Arch Pathol Lab Med. 2010 Jul;134(7):e48-72. doi: 10.5858/134.7.e48.
9
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.美国临床肿瘤学会/美国病理学家学会关于乳腺癌中人表皮生长因子受体2检测的指南建议
Arch Pathol Lab Med. 2007;131(1):18-43. doi: 10.5858/2007-131-18-ASOCCO.
10
Same question, different data source, different answers? Data source agreement for surgical procedures on women with breast cancer.同样的问题,不同的数据来源,不同的答案?乳腺癌女性手术程序的数据来源一致性
Healthc Policy. 2007 Aug;3(1):46-54.